"Many of my patients with multidrug-resistant recurrent urinary tract infections have tried multiple antibiotics for years without success," said Liz D'Antonio, CRNP, director of clinical research, Anne Arundel Urology. " A vaccine presents a new approach that could offer new hope for these patients. We eagerly await the results of the next studies as it hopefully moves toward approval."
The first total synthesis of bifidenone, a novel natural tubulin polymerization inhibitor, has been achieved in 12 steps starting from commercially available starting materials. Bifidenone is the plant compound that inspired SQ1274, Sequoia's compound in development as an anticancer compound.